PT  - JOURNAL ARTICLE
AU  - Clemens Kratochwil
AU  - Frank Bruchertseifer
AU  - Frederik L Giesel
AU  - Mirjam Weis
AU  - Frederik A Verburg
AU  - Felix Mottaghy
AU  - Klaus Kopka
AU  - Christos Apostolidis
AU  - Uwe Haberkorn
AU  - Alfred Morgenstern
TI  - <sup>225</sup>Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer
AID  - 10.2967/jnumed.116.178673
DP  - 2016 Jul 01
TA  - Journal of Nuclear Medicine
PG  - jnumed.116.178673
4099  - http://jnm.snmjournals.org/content/early/2016/07/27/jnumed.116.178673.short
4100  - http://jnm.snmjournals.org/content/early/2016/07/27/jnumed.116.178673.full
AB  - Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac- PSMA-617 therapy. Methods: 68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT. Results: Both patients experienced a prostatespecific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect. Conclusion: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.